The latest manufacturer of major antibiotic substances in Europe closes the largest local factory

Be informed with free updates

Simply register Pharmaceutical sector Myft Digest – Delivered directly to your box.

For some vital antibiotics, the manufacturer of Europe closes the largest local factory, and some extractions are taking part to China, Brussels to China to reduce drug addiction.

Many pharmacy, said that it could only be survived by the Chinese competition, taking part in the plant there.

Half of the active drugs of the huge (API) of the active drugs AB List of critical drugs and a list of the necessary medicines of the World Health Organization.

Danish company Tuesday will close the Copenhagen plant, which resulted in the loss of 500 jobs. It will still keep the European operation more effective in Budapest.

His CEO Michael Kocher said that the general medicines of state-funded health systems are not prepared to pay more for more companies Eu I would move the factories.

“We are very discussing again. I think that those in Europe are important to make sure we are in Europe,” he said.

The drug contains Vancomycin hydrochloride, which is necessary to produce antibiotics that can treat violent infections such as Sepsis, who are sepsis, which are sepsis.

The relative of the API used in the EU is already coming from China. With tension systems that do not want to increase their medical prices, Kocher claimed that the EU was the only way to ensure a control over important substances.

“Otherwise, only 80 percent of the API will come from China. It will soon be about 100 percent,” he said.

Kocher stressed that Western demand for Vancomycin hydrochloride can still be met from Budapest.

In March, the European Commission tries to touch off proposals that can be entered into critical medicines, Covid-19 pandemology, the short term of protective clothing and equipment such as countries, ventilators, protective clothing and equipment.

These proposals aim to increase more than 4 drug production from antibiotics, such as Penicillin and Erithromycin, such as Penicillin and Erithomycin, such as Penicillin and Erithomycin.

The measures discussed allow the countries to participate in the bulk purchases and to prefer the EU-made products in procurement processes. But Kocher said policies took a very shy and very long way to carry out.

“Expenses are growing, you are trying to transfer these expenses to your customers, and then your customers decide that the costs are very high and increase the share from China,” he said. “We are looking for … obligation to support continuous operations.”

Research and strong pharmaceutical companies also warned that the few prices paid by European health systems are making new drug discovery to the United States and China.

The heads of Novartis and Sanofi wrote to the commission last month Call at a higher price. They also said that companies wanted to invest in North America. But Khellia said there was no plan for it.

Many NOVO Holdings, Denmark Pharmaceutical Strengthen Novo Nordisk *, sells more than 500 enterprises in 80 countries. It will take ten years to hand over the production from the Copenhagen factory elsewhere.

Kocher should value more values ​​for “life-saving” products that treat the EU, Menornit and other deadly conditions. “Without our productive portfolio, we will face a big problem. There would be a small issue compared to the covel.”

*This article was updated to clarify the property of Hellia.